Optic Neuritis
Conditions
Brief summary
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.
Interventions
DRUGEdaravone
Edaravone injection 30mg three times a day
Sponsors
First Affiliated Hospital of Guangxi Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis 2. Patients with a first episode of optic neuritis in either eye 3. First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone
Exclusion criteria
1. Myopia over 6 diopters 2. Refractive media opacity affecting assessment of retinal layers and/or visual acuity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Best-corrected visual acuity | 18 months | Best-corrected visual acuity will be measured by Illiterate Echart. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ganglion cell-inner plexiform layer | 18 months | Ganglion cell-inner plexiform layer will be measured by optical coherence tomography. |
| Peripapillary retinal nerve fiber layer | 18 months | Peripapillary retinal nerve fiber layer will be measured by optical coherence tomography. |
Countries
China
Outcome results
None listed